Log in Free sign up

Selecta Biosciences (SELB) News and press releases

News

From Benzinga Pro

Expert Ratings for Selecta Biosciences

Analyst Ratings

Over the past 3 months, 4 analysts have published their opinion on Selecta Biosciences (NASDAQ:SELB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

HC Wainwright & Co. Maintains Buy on Selecta Biosciences, Lowers Price Target to $4

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $6 to $4.

63 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.

Needham Maintains Buy on Selecta Biosciences, Lowers Price Target to $5

News, Price Target, Analyst Ratings

Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $6 to $5.

Selecta Biosciences Announces Partnership Advancements And Clinical Trial Updates; Selecta To Receive A $2M Payment From Sarepta Plus Up To $10M In Potential Achievements

Biotech, News, Contracts, General

-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta extending their

91 Biggest Movers From Friday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.

44 Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.

SVB Leerink Sees Over 600% Upside For This Penny Biotech Stock

Analyst Color, Biotech, News, Penny Stocks, Health Care, Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas, General

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

SVB Leerink Initiates Coverage On Selecta Biosciences with Outperform Rating, Announces Price Target of $7

News, Price Target, Initiation, Analyst Ratings

SVB Leerink analyst Joseph Schwartz initiates coverage on Selecta Biosciences (NASDAQ:SELB) with a Outperform rating and announces Price Target of $7.

24 Stocks Moving in Thursday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).

Executives Buy Around $1.5M Of 4 Penny Stocks

Long Ideas, News, Penny Stocks, Small Cap, Insider Trades, Markets, Trading Ideas

US stock futures traded lower this morning on Thursday ahead of the producer price index. Investors, meanwhile, focused on some notable insider trades.

Needham Maintains Buy Rating for Selecta Biosciences: Here's What You Need To Know

Analyst Ratings

Needham has decided to maintain its Buy rating of Selecta Biosciences (NASDAQ:SELB) and lower its price target from $7.00 to $6.00. Shares of Selecta Biosciences are trading up 2.84% over the last 24 hours, at $0.83 per share.

Needham Maintains Buy on Selecta Biosciences, Lowers Price Target to $6

News, Price Target, Analyst Ratings

Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $7 to $6.

Recap: Selecta Biosciences Q1 Earnings

Selecta Biosciences (NASDAQ:SELB) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study

Biotech, Earnings, News, Penny Stocks, Health Care, Contracts, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Selecta Biosciences Q1 EPS $0.08 Up From $(0.22) YoY

Selecta Biosciences (NASDAQ:SELB) reported quarterly earnings of $0.08 per share. This is a 136.36 percent increase over losses of $(0.22) per share from the same period last year.

Earnings Scheduled For May 5, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

Earnings Outlook For Selecta Biosciences

Selecta Biosciences (NASDAQ:SELB) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Selecta Biosciences will report an earnings per share (EPS) of $-0.11.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Wednesday's trading, 435 companies set new 52-week lows.

Press releases

From Benzinga Pro

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates

Health Care, Analyst Ratings, Press Releases

-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta extending their

Thinking about buying stock in Applied UV, Nio, Wejo Group, Helius Medical Technologies, or Selecta Biosciences?

Opinion, Press Releases

NEW YORK, June 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, NIO, WEJO, HSDT, and SELB.

Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

News, Press Releases

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Earnings, Press Releases

– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten

Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

News, Press Releases

WATERTOWN, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

News, Press Releases

WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that

Selecta Biosciences Announces $38.7 Million Underwritten Offering

WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB) ("Selecta" or the "Company"), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune